Bonesupport: Solid performance in Q4 – critical juncture up ahead - Redeye

Redeye notes another record quarter for BONESUPPORT and is encouraged by the persistent sales growth during a most peculiar year for elective surgeries. We reiterate our Base Case of SEK 80 and argue that the stock could soon see a fairer price closer to its peers, with a potential FDA approval as a clear trigger.

Länk till analysen i sin helhet: https://www.redeye.se/research/833598/bonesupport-solid-performance-in-q4-critical-juncture-up-ahead?utm_source=finwire&utm_medium=RSS